1. Home
  2. People
  3. Barr, Laura Rose

Laura Rose Barr

Partner

シアトル

Laura, co-leader of Orrick's global Technology & Innovation sector, works with some of the most innovative thinkers in the world. She takes legal pain points for entrepreneurs - negotiating with VCs, getting team equity right and protecting IP - and makes them easy at every stage.

Laura co-leads Orrick's Artificial Intelligence initiative and is a founding member of Orrick’s Technology Companies practice in the Pacific Northwest. She is passionate about working with women founders, other underrepresented entrepreneurs, and double bottom line companies. People who think differently, and set out to create impact, inspire her.

She represents companies and their investors in a variety of verticals, including AI & Machine Learning (Anthropic), consumer applications (AppSheet, Life360, Mylio), education technology (Brisk Teaching, Go1), financial technology (Further AI, SoFi), information security (Doppel, Stairwell) and life sciences (Charta, Dandelion Health, Ophelia Health), among others. 

In addition to start-up representation, she regularly provides pro bono legal advice to charitable organizations regarding non-profit incorporation and tax exemption applications.

    Amber.io (d/b/a Two Tap)
    • $9.5 million sale to Honey
    Appsheet
    • $19.3 million Series A financing
    • Acquisition by Google
    BoomTV
    • $8.8 million Series A financing
    CelLink 
    • $22.5 million Series B financing
    CI Security
    • $6.4 million Series A financing
    • $16 million Series B financing
    Convoy
    • $185 million Series C financing
    • $400 million Series D financing
    Cortexyme
    • $76.9 million Series B financing
    • $75 million IPO on NASDAQ
    Credible
    • $50.9 million IPO on ASX
    Curebase
    • $2.5 million Series Seed financing
    Getaround 
    • $300 million Series D financing
    • $300 million acquisition of Drivy
    Grabango
    • $18.1 million Series A financing
    Ladder Financial
    • $30 million Series B financing
    Life360
    • $28 million Series D financing
    • $120.1 million IPO on ASX
    M12
    • $230 million Series C investment in Psiquantum
    • $70 million Series F investment in BlueVine
    • $10 million Series B investment in Skedulo Holdings, Inc
    • $25 million Series B investment in Syntiant
    Oisin Biotechnologies
    • $3 million Safe financing
    OncoSenX
    • $3 million Seed financing
    Social Finance (d/b/a SoFi)
    • General corporate advisement on its $1.2 billion acquisition of Galileo
    Solfice Research (d/b/a Civil Maps)
    • $9.4 million Series A financing
    Varian Medical Systems
    • $140 million Series B investment in Fusion Pharmaceuticals